Tenofovir Alafenamide-Based Therapies for HIV - The Study
Two studies published in the Lancet HIV support guidelines recommending tenofovir alafenamide (TAF)-based regimens for the treatment of HIV.
#Tenofovir alafenamide (TAF)-based regimens are recommended for the treatment of HIV in the last two studies published in the Lancet HIV.
In the first study, researchers analysed the safety and efficacy of a single-tablet combination of emtricitabine, rilpivirine, and TAF compared with a rilpivirine, emtricitabine, and tenofovir disoproxil fumarate (#TDF) regimen.
“These findings support guidelines recommending tenofovir alafenamide-based regimens, including coformulation with rilpivirine and emtricitabine, as an initial and ongoing treatment for HIV-1 infection,” the contributors wrote.
Shifting from TDF-based regimens to TAF-regimens in the treatment of HIV has also shown promise in other clinical trials. Gilead announced positive results from a 96-week, phase 3 trial evaluating the safety and efficacy of switching from regimens containing Truvada (TDF-based) to those containing Descovy (TAF-based).
The findings from this study noticed that the regimens that included Descovy confirmed non-inferiority to those containing Truvada. Moreover, patients administered Descovy had improvements in renal and bone laboratory parameters.